Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)

This study has been terminated.
(Study halted prematurely due to low accrual.)
Information provided by (Responsible Party):
Medical University of South Carolina Identifier:
First received: June 4, 2010
Last updated: June 8, 2016
Last verified: February 2016
This is study is for patients that have been diagnosed with high-risk hematological malignancies. The main purpose of this study is to confirm previously published results of stem cell transplantation with reduced intensity pre-transplant conditioning. Patients will be assigned to 1 of 3 regimens depending on the patient's diagnosis. Participants will be followed by the transplant team for the remainder of the patient's life. Patient's will visit MUSC daily, then visits will be reduced to frequent visits for up to 6 months. After 6 months, the visits will be reduced more depending on the patient's condition.

Condition Intervention Phase
Hematological Malignancies
Drug: Regimen A
Drug: Regimen B
Drug: Regimen C
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Allogeneic Hematopoietic Stem Cell Transplantation With Reduced-Intensity Pre-Transplant Conditioning for the Treatment of High-Risk Hematological Malignancies

Further study details as provided by Medical University of South Carolina:

Primary Outcome Measures:
  • To Determine the Treatment-related Mortality Rate of Allogeneic Stem Cell Transplants Using Reduced-intensity Conditioning Regimens Within 1st 100-days. [ Time Frame: 8 years ]
    Number of subject deaths prior to day 100.

Secondary Outcome Measures:
  • To Determine the Engraftment Rate of Allogeneic Stem Cell Transplants [ Time Frame: Day +100 ]
    To determine the engraftment rate of allogeneic stem cell transplants using reduced-intensity conditioning regimens. It will be measured as the proportion of subjects meeting criteria for engraftment before day +30 and full donor chimerism demonstrated before or at day +100. Engraftment is defined by maintenance of ANC > 500/mm3 for at least 3 consecutive days and platelet count > 20,000/mm3 for 3 consecutive days in absence of platelet transfusion. These criteria must have been met before Day +30. Chimerism is the pressence of donor cells and will be analyzed by FISH for sex-mismatched donor-recipient pairs and VNTR analysis for sex-mathced pairs. Chimerism by Day +100 will be documented for this outcome

  • Morbidity of Allogeneic Stem Cell Transplants [ Time Frame: 100 days ]
    To determine the morbidity, including the pattern and severity of complications, of allogeneic stem cell transplants using reduced-intensity conditioning regimens. The average number of days spent in the hospital until day +100 will be reported as a surrogate for morbidity and complications.

Enrollment: 78
Study Start Date: June 2010
Study Completion Date: December 2015
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single Arm, non-randomized study Drug: Regimen A
Chronic Lymphocytic Leukemia/ Chronic Prolymphocytic Leukemia, Multiple Myeloma.
Drug: Regimen B
Other malignancies not addressed in A or C
Drug: Regimen C
B-Cell Lymphomas


Ages Eligible for Study:   1 Year to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A proven diagnosis of one of the conditions in Table 1.
  • Prior therapy including blood or marrow transplant will not exclude patients for reduced intensity transplant.
  • Age < 75 years. Pediatric patients are eligible from the ages of 1 month to 18 years if the transplant physician believes that co-morbid conditions significantly increase the risk for a standard transplant regimen.
  • HIV antibody negative.
  • ECOG performance status 0-3, (or equivalent Karnofsky and Lansky performance scores for patients <18yrs, see appendix 2)
  • Availability of an HLA-identical related donor or suitable alternative donor, (≥7/8 allele match at A, B, C and DRB). Syngeneic transplants will not be allowed in this protocol.
  • Due to the complexity of the study, all patients prior to enrollment will be assessed by the PI or co-PI.
  • Patient with marrow failure states or immune deficiency syndromes undergoing stem cell transplants must be reviewed by one of the investigators to determine eligibility for study.
  • Adequate insurance coverage (or financial resources) to cover the costs associated with the patient's transplant and, in the case of patients eligible for cohort C, to cover the costs associated with I 131 Tositumomab treatment.

Exclusion Criteria:

  • Active CNS involvement with malignant disease.
  • Pregnancy.
  • Fertile men or women unwilling to use contraceptive techniques during the study period.
  • Creatinine clearance < 30 ml/min.
  • Left ventricular ejection fraction <30% or clinical cardiac failure uncontrolled by medical therapy.
  • Pulmonary disease requiring supplemental oxygen therapy.
  • Patients with estimated life span less than 1 year due to medical illnesses other than the condition being treated on the study.

Donor Selection:

Inclusion Criteria

  • Major HLA identical relative or genotypically matched unrelated donor (7-8/8 alleles) .
  • Donors must meet the selection criteria as defined by the Foundation for the Accreditation of Cell Therapy (FACT) and will be screened per the American Association of Blood Banks (AABB) guidelines.

Exclusion Criterion

  • Positive anti-donor HLA antibody.
  • Identical twin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01139164

United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
Medical University of South Carolina
Principal Investigator: Robert Stuart, MD Medical University of South Carolina
  More Information

Responsible Party: Medical University of South Carolina Identifier: NCT01139164     History of Changes
Other Study ID Numbers: 101370
HR#19490 ( Other Identifier: MUSC IRB )
Study First Received: June 4, 2010
Results First Received: February 11, 2016
Last Updated: June 8, 2016

Keywords provided by Medical University of South Carolina:
high-risk hematological malignancies

Additional relevant MeSH terms:
Neoplasms processed this record on May 25, 2017